Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2010
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
Sabbatical Leave
Hybrid Work Options
401(k) Company Match
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Wellness Program
Mental Health Support
Phone/Internet Stipend
Home Office Stipend
Tempus enters multiyear collaboration with Moderna, Merck aimed at commercializing cancer drug. Published on 10/07/2026 at 09:26 am EDT - Modified on 10/07/2026 at 09:27 am EDT By Kelly Cloonan Tempus is doubling down on its work with Moderna and Merck under a new multiyear collaboration to support the potential commercialization of a cancer drug. The healthcare-technology company said Wednesday the collaboration will focus on intismeran autogene, a therapy being evaluated in combination with Merck's Keytruda in patients with completely resected stage IIB-IV melanoma and other cancer types. Moderna and Merck are jointly developing intismeran autogene. As part of the collaboration, Tempus will manage the collection and transfer of tumor tissue and blood samples required for next-generation sequencing, the company said. The collaboration expands work that Tempus initiated with Moderna and Merck last year. Moderna said working with Tempus will allow it to use the company's commercial footprint and advanced sequencing capabilities to help it provide individualized neoantigen therapies at scale. "Bringing an individualized therapy like intismeran autogene from clinical development toward potential commercialization requires a seamless, highly reliable diagnostic network," said Said Francis, Moderna's chief business officer and general manager, individualized neoantigen therapies. Write to Kelly Cloonan at [email protected] (END) Dow Jones Newswires 10-07-26 0925ET (C) Dow Jones - 2026
Tempus announces multi-year collaboration with Moderna and Merck. Key Takeaway: Tempus has announced a multi-year collaboration with Moderna and Merck to support the commercialization of intismeran autogene, a novel individualized neoantigen therapy. This therapy is being evaluated in combination with Merck's KEYTRUDA for patients with completely resected stage IIB-IV melanoma and other cancers. The collaboration signifies a significant step in cancer treatment innovation. Market sentiment analysis. Positive factors. * Collaboration aims to support commercialization of innovative therapy. * Intismeran autogene is a potential first-in-class treatment. * Combination therapy with KEYTRUDA may enhance cancer treatment options. BiopharmaWatch analysis. From its catalyst data and publicly available data · not financial advice Best trade, last catalyst 120-day peak, hindsight Typical move average across 9 past catalysts Cash runway Minimal dilution risk Lead asset Phase 2 · Influenza CHICAGO-(BUSINESS WIRE)-Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA(R)(pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, know Frequently asked questions. What is the focus of the Tempus collaboration? The collaboration focuses on supporting the commercialization of intismeran autogene. Which therapy is intismeran autogene combined with? Intismeran autogene is evaluated in combination with KEYTRUDA. What types of cancer are targeted in this collaboration? The collaboration targets completely resected stage IIB-IV melanoma and other cancers. Who are the partners in the collaboration? The partners are Tempus, Moderna, and Merck.
Labor boosts pandemic defence as world seeks answers on Russian plague. Oct 7, 2026 - 10.30pm The Albanese government has boosted Australia's capacity to respond to pandemics and biosecurity threats, as global health authorities seek answers from Russia following the death of a laboratory worker from pneumonic plague. While the World Health Organisation has downplayed the risk of a wider outbreak from the Russian incident, the federal government has established a five-year partnership linking the expertise of the publicly owned CSIRO and biotechnology giant Moderna.
Moderna shares fell 6% in premarket trading Wednesday after Citi downgraded the stock from Neutral to Sell, citing stretched valuation following a 222% rally since positive cancer vaccine trial results. Citi analyst Geoff Meacham noted Moderna's market capitalisation now matches Regeneron despite materially lower expected revenue and earnings. He raised his price target to $80 from $60, though this remains well below the current share price. The rally followed positive August results from the INTerpath-001 melanoma trial, which tested Moderna's individualised mRNA cancer vaccine with Merck's Keytruda. Detailed data will be presented at the European Society for Medical Oncology Congress in October. Moderna is bringing back former executive Juan Andres as chief operating officer to lead manufacturing ahead of a potential launch. The stock has surged 556% year to date.
US stock index futures traded near flat on Wednesday as investors awaited key inflation data and semiconductor earnings. The personal consumption expenditures price index, the Federal Reserve's preferred inflation gauge, is due later today and expected to show inflation remaining above the central bank's 2% target. Boeing surged 3% in premarket trading after winning a contract worth over $20 billion to develop the US Navy's next-generation carrier-based strike fighter, the F/A-XX. The award beat rival Northrop Grumman and marks Boeing's second consecutive sixth-generation fighter programme win. Concentrix plunged 11.1% after reporting disappointing revenue and guidance. The company forecast fourth-quarter revenue to decline 3% to 5%, citing faster-than-expected AI automation among clients.